Company intelligence / Profile preview

Perseid Therapeutics

Redwood City, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Perseid Therapeutics was a joint venture focused on protein-therapeutic drugs, primarily developing next-generation CTLA4-Ig protein therapeutics such as MAXY-4 for immune modulation in transplantation and autoimmune disease. There are no reported clinical results as the company was acquired and later closed before programs advanced to late-stage trials.

Therapeutic areas: Immunology
Modalities: Protein
Industry: Biotech

Partnerships

Maxygen

Beyond the preview

Go deeper on Perseid Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perseid Therapeutics.

Explore the full profile